Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.

Autor: Lopes Cardozo JMN; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Byng D; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Drukker CA; Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Binuya MA; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., van 't Veer LJ; Department of Laboratory Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal., Piccart M; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Smorenburg CH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Poncet C; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Rutgers EJT; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: e.rutgers@nki.nl.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Mar; Vol. 33 (3), pp. 310-320. Date of Electronic Publication: 2021 Dec 01.